Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients

Endocrine Journal

Volumn 52, Issue 2, 2005, Pages 259-264

  Miwa, Shinnya ^a   Watada, Hirotaka ^a   Omura, Chie ^a   Takayanagi, Naoko ^a   Nishiyama, Kyoko ^a   Tanaka, Yasushi ^a   Onuma, Tomio ^a   Kawamori, Ryuzo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

HMG CoA reductase inhibitor; Oxidative stress; Type 2 diabetes

Indexed keywords

3,5,7 CHOLESTATRIENE; 8 ISOPROSTAGLANDIN F2 ALPHA; ALPHA TOCOPHEROL; CHOLESTEROL; CHOLESTEROL DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PRAVASTATIN; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; HYPERLIPIDEMIA; JAPAN; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROSTAGLANDIN BLOOD LEVEL;

AGED; ANTIOXIDANTS; CHOLESTENES; CHOLESTEROL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; ERYTHROCYTE MEMBRANE; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INDOLES; MALE; MIDDLE AGED; OXIDATIVE STRESS; PRAVASTATIN; PROSPECTIVE STUDIES; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 19744376800     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.52.259     Document Type: Article

References (19)

1. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335: 1001-1009.
2. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4s). Lancet 344: 1383-1389.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group. N Engl J Med 333: 1301-1307.
4. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of hmg-coa reductase. Atherosclerosis 101: 117-125.
5. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K (2003) Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb 10: 37-42.
6. Kearney D, Fitzgerald D (1999) The anti-thrombotic effects of statins. J Am Coll Cardiol 33: 1305-1307.
7. Marz W, Wieland H (2000) Hmg-coa reductase inhibition: Anti-inflammatory effects beyond lipid lowering? Herz 25: 117-125.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (cards): Multicentre randomised placebo-controlled trial. Lancet 364: 685-696.
9. Suzumura K, Yasuhara M, Tanaka K, Suzuki T (1999) Protective effect of fluvastatin sodium (xu-62-320), a 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 57: 697-703.
10. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622.
11. Miwa S, Inouye M, Ohmura C, Mitsuhashi N, Onuma T, Kawamori R (2003) Relationship between carotid atherosclerosis and erythrocyte membrane cholesterol oxidation products in type 2 diabetic patients. Diabetes Res Clin Pract 61: 81-88.
12. Slater TF, Sawyer BC (1971) The stimulatory effects of carbon tetrachloride on peroxidative reactions in rat liver fractions in vitro. Inhibitory effects of free-radical scavengers and other agents. Biochem J 123: 823-828.
13. Devaraj S, Hirany SV, Burk RF, Jialal I (2001) Divergence between ldl oxidative susceptibility and urinary f(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 47: 1974-1979.
14. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M (1994) Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215: 121-125.
15. Miwa S, Watada H, Ohmura C, Tanaka Y, Kawamori R (2004) Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide. Endocr J 51: 393-398.
16. Plosker GL, Wagstaff AJ (1996) Fluvastatin: A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 51: 433-459.
17. Chen MF, Hsu HC, Lee YT (1997) Short-term treatment with low-dose pravastatin attenuates oxidative susceptibility of low-density lipoprotein in hypercholesterolemic patients. Cardiovasc Drugs Ther 11: 787-793.
18. Girona J, La Ville AE, Sola R, Plana N, Masana L (1999) Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83: 846-851.
19. Aviram M, Rosenblat M, Bisgaier CL, Newton RS (1998) Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 138: 271-280.